The left ventricle (LV) typically dominates the conversation around cardiovascular risk. This includes symptoms stemming from LV ischemia, signs of increased LV voltage by electrocardiography in hypertensive heart disease and, apparently, a focus on the LV to open an editorial devoted to the right ventricle (RV) in preclinical risk assessment.
That is not to say that the softer voice of the distressed right ventricle (RV) cannot be heard. While the RV generally labors in the shadow of the more massive LV, the astute clinician can 'think right heart' 1 in the appropriate context of, for instance, a history of pulmonary or congenital heart disease. Furthermore, RV abnormalities can be recognized upon careful (RVH) doubled risk of incident heart failure and cardiovascular death. This was observed in a cohort of mildly overweight adults in their early 60s who were, on average, normotensive at the time of baseline examination. In 65% of the study sample who had pulmonary function tested roughly 2 years after baseline assessment, the incremental predictive value of RVH for HF or death over the same covariates remained significant. 6 . In this study, 69% of subjects had measurable tricuspid regurgitation (TR), considerably higher than a peak 26% prevalence (increasing with age and highest in octogenarian men) of mild or worse TR in the Framingham study 7 . In contrast, 92% (4144/4484) of the present MESA cohort had interpretable RV-CMR studies. While these data suggest that RV mass is a more reliable biomarker of right heart disease in communitybased cohorts, some context of RVH by CMR amidst widely used echo-Doppler measurements would have been helpful.
Is the RV speaking to us directly through Kawut and colleagues' parsimonious model, or is it simply a voice for so many unmeasured variables? While a subset had pulmonary function tests that would presumably capture latent obstructive or interstitial lung disease, we do not know to what extent sleep disordered breathing, occupational or travel exposures, silent chronic thromboembolism, undiagnosed left to right shunts and infections such as human immunodeficiency virus were responsible for right heart changes. Of these variables, sleep baseline evaluation, increased PASP conferred increased mortality in a stepwise e fa f fash sh s io io on n (a (a (age ge ge--adjusted hazard ratio of 2.74 per 10 mm Hg) 6 . In this study, 69% of subjects had measurable ri ricu cu usp sp spid id id r r reg eg egu u urgi gita ta tati ti t on (TR), considerably highe er r r th than a peak 26% % % prev ev val al alen e ce (increasing with ag ge e an a d highes est t in i i oct ctog og gen en enar ar aria ia ian n m me men) n) n o of f f mil l ld or wo wo worse e e T TR TR in n n th the e e F Fr Fram am min ngh gham am am s stu tu udy dy y 7 7 7 . . In In c con on ntr r rast Events such as heart failure (N=78, 2%) and cardiovascular death (N=34, 0.8%) were expectedly low. This number of events still allowed for subset analysis by pulmonary function measures, but the primary analysis did not include several key risk factors for heart failure that were addressed in an earlier publication in this journal reporting heart failure events in the MESA-RV cohort 10 .
In that work, a high prevalence of baseline hypertension, obesity, COPD, smoking, LV hypertrophy and LV systolic dysfunction were rated as significant contributors to subsequent heart failure. Those results remind us of the difficulty in attributing events to RV hypertrophy beyond what could be predicted by classic left heart failure risk factors.
The finding of a higher event rate in subjects with RV hypertrophy in conjunction with a relatively low LV mass is interesting, and is perhaps accounted for by the LV's propensity to overwhelm the RV's independent contribution to symptoms in the vast majority of heart failure cases and cardiovascular deaths. This is evident in the moderating effect of LV indices on the clinical impact of the other RV measures that did not survive multivariable analysis, such as RV end-diastolic and end-systolic volumes. These data endorse an association between RV mass and events, but causation requires further investigation.
Even as CMR offers a gold standard to quantify RV size and systolic function, the assessment of RV mass can be time-consuming and prone to significant inter-observer variability without dedicated core laboratory facilities or clinical staff adept at RV endocardial and MESA-RV cohort 10 .
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The right ventricle is susceptible to dysfunction concomitantly with the LV due to not only increases in afterload from pulmonary venous hypertension but also ventricular interdependence, shared cellular myopathic processes and ischemia. Evidence describing separate LV and RV embryogenesis, with recent discovery of a 'second heart field' from which the RV (but not the LV) develops hypertrophy y wi wi w th th t ou ou out t t fa fa fail il i ur r re e e vi vi v a a pu pu pulm lm mon n nar ar ary y y ar ar arte te tery ry ry ba ba band nd n in in ng g g in in in S S Spr pr prag ag gue ue ue--Da Da Dawl wl wley ey y r r rat at ats, s, s, w w whe h reas RV mechanisms to explain RV dysfunction in humans are gaining momentum but remain rudimentary compared to the LV 16 . Recognizing these gaps, a working group of the National Heart, Lung and Blood Institute has delineated a roadmap to target translational research in these critical areas 5 .
This work is a valuable and provocative addition to the literature that lends a stronger voice to the soft-spoken RV, which may be the 'good listener' among cardiac chambers -taking in the effects of a variety of other conditions and presenting it through structural changes to the attuned observer. This trial's meticulous measurement of RV parameters coupled with long-term follow-up represents an important step forward in population-based research that should foster novel translational efforts. Ultimately, multifaceted, longitudinal outcomes studies that track the onset and progression of structural and functional changes should yield better identification of atrisk individuals who would benefit from population-based strategies to prevent adverse cardiovascular events.
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